Analyst Rating: Will NextCure Inc (NXTC) Stock Lead the Market?

Wall Street is positive on NextCure Inc (NXTC). On average, analysts give NXTC a Buy rating. The average price target is $5, which means analysts expect the stock to rise by 275.94% over the next twelve months. That average ranking earns NXTC an Analyst Rating of 30, which is better than 30% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating NXTC a Buy today. Find out what this means to you and get the rest of the rankings on NXTC!

See Full NXTC Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With NextCure Inc Stock Today?

NextCure Inc (NXTC) stock has risen 0.77% while the S&P 500 is lower by -0.97% as of 10:52 AM on Tuesday, Sep 26. NXTC has risen $0.01 from the previous closing price of $1.32 on volume of 14,022 shares. Over the past year the S&P 500 has gained 17.52% while NXTC is lower by -53.00%. NXTC lost -$2.53 per share the over the last 12 months. Click Here to get the full Stock Report for NextCure Inc stock.